The company’s technologies possess the powerful feature that they can be applied in very different indications, and MorphoSys scientists use them against a wide range of targets. But no company can take advantage of all these opportunities alone. Together with its partners, MorphoSys is currently developing more than 100 different antibody programs for the treatment of various diseases such as cancer, Alzheimer’s disease, infectious diseases, cardiovascular dysfunction and inflammation. The partnered pipeline includes novel approaches with exciting prospects such as guselkumab, anetumab ravtansine and gantenerumab.
In order to expand its portfolio of unique drug candidates, MorphoSys is continuously looking for partners with innovative targets, supportive technologies and promising antibodies for further development.